Knowledge Tree
Relations (1)
related 4.46 — strongly supporting 21 facts
Ketamine is a pharmacological intervention extensively studied for its rapid antidepressant effects and therapeutic potential in treating depression, as evidenced by clinical trials and systematic reviews [1], [2], [3]. Furthermore, specific administration protocols like the Montreal model have been developed to utilize ketamine for managing depression symptoms [4], [5].
Facts (21)
Sources
The Montreal model: an integrative biomedical-psychedelic ... frontiersin.org 18 facts
claimPsilocybin currently has stronger evidence than ketamine supporting the therapeutic potential of 'emotional breakthroughs' and mystical experiences in the treatment of depression.
claimKetamine can provide 'windows of opportunity' for symptomatic relief from depression and psychologically beneficial treatment experiences, both of which facilitate longer-term efforts toward recovery.
referencePolis et al. examined the variability in rodent ketamine depression-related research, published in Behavioural Brain Research in 2019.
claimKetamine and psilocybin can both produce rapid improvements in psychiatric conditions like depression that persist for days or weeks beyond the excretion of the drugs and their metabolites.
referenceRosenblat et al. (2019) conducted a systematic review on the use of oral ketamine for the treatment of depression.
referenceSmith-Apeldoorn et al. published a 2022 systematic review in The Lancet Psychiatry on the efficacy, safety, and tolerability of maintenance ketamine treatment for depression.
claimThe Montreal model recommends screening for obstructive sleep apnea during the medical history assessment for ketamine treatment, as it is a condition commonly associated with depression.
claimThe Montreal model of ketamine administration may be valuable for treating patients grappling with depression in the final stages of life.
referenceAndrade (2017) reviewed clinical parameters for ketamine use in depression, specifically addressing dosage, rate of administration, route, duration, and frequency.
referenceHassan et al. (2022) performed a retrospective study on the safety, effectiveness, and tolerability of sublingual ketamine for the treatment of depression and anxiety in an at-home, off-label setting.
referenceA clinical trial titled 'Music as an intervention to improve hemodynamic tolerability of ketamine in depression' is registered on ClinicalTrials.gov (NCT04701866) as of 2023.
referenceFeifel, Dadiomov, and Lee published a 2020 study in Pharmaceuticals regarding the safety of repeated parenteral ketamine administration for depression.
referenceHull et al. (2022) conducted a large, prospective, open-label effectiveness trial which found that at-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression.
referenceGarel et al. explored the potential role of ketamine for depression in requests for medical aid in dying, published in International Clinical Psychopharmacology in 2023.
claimKetamine and serotonergic psychedelics are re-emerging as potential treatments for depression, generating considerable interest.
procedureThe Montreal model of ketamine treatment for depression is conducted similarly to acute treatments, with an emphasis on revisiting behavioral goals and experiential learning.
claimKetamine's rapid benefits against suicidality and the cognitive impairments of depression theoretically reduce obstacles to productive psychotherapy.
claimNo published clinical trial has explored the use of ketamine with concomitant psychotherapy to treat depression.
Ancient Roots of Today's Emerging Renaissance in ... link.springer.com 2 facts
referenceAlexandrine Corriger and Gisele Pickering published a narrative review in 2019 titled 'Ketamine and depression' in the journal Drug Design, Development and Therapy.
claimThere is a robust literature of studies establishing the safety and efficacy of ketamine-assisted treatment for depression (Salahudeen et al. 2020) and increasingly high-quality studies on psilocybin-based therapies for depression (Carhart-Harris et al. 2021; Davis et al. 2020), though larger and more robust clinical trials are still needed.
Effects of psychedelics on neurogenesis and broader neuroplasticity link.springer.com 1 fact
claimThe discovery of ketamine's rapid antidepressant effect was considered by some researchers the greatest breakthrough in depression research over the past half-century.